Exact Sciences Corporation

NASDAQ•EXAS

CEO: Mr. Kevin T. Conroy J.D.

Sector: Healthcare

Industry: Medical - Diagnostics & Research

Listing Date: 2001-02-01

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Contact Information

5505 Endeavor Lane, Madison, WI, 53719, United States

608-284-5700

www.exactsciences.com

Market Cap

$19.80B

P/E (TTM)

-94.6

19.8

Dividend Yield

52W High

$103.75

52W Low

$38.81

52W Range

100%

Rank62Top 92.6%

1.9

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 1.9 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$878.38M+0.00%

4-Quarter Trend

EPS

-$0.45+0.00%

4-Quarter Trend

FCF

$120.45M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Grew 17.7% Total revenue reached $3.25B USD in 2025, driven by 20.2% growth in Screening revenue segment.

Net Loss Significantly Narrowed Net loss reduced to $207.9M USD in 2025, a substantial improvement from $1.03B USD loss last year.

Operating Cash Flow Improved Cash provided by operating activities was $491.4M USD, reflecting a $280.9M USD improvement over 2024.

Abbott Merger Agreement Signed Entered Merger Agreement with Abbott for $105.00 cash per share; expected consummation in Q2 2026.

Risk Factors

Merger Execution Uncertainty Failure or delay in closing the Abbott Merger could materially affect operations and common stock price.

Dependence on Product Success Success heavily relies on commercialization of Screening and Precision Oncology tests in development pipeline.

Regulatory and Reimbursement Risks Uncertainty exists related to healthcare reform, pricing, coverage, and maintaining adequate reimbursement rates.

Need for Additional Capital Additional capital may be required to fully fund strategic plan; financing availability or terms are uncertain.

Outlook

Productivity Plan Implementation Implementing multi-year productivity plan targeting over $150M USD in expected annual savings by 2026.

Pipeline Development Investment Expect continued significant investment in R&D to enhance current products and advance pipeline offerings.

Next-Generation MRD Test Launch Plan to introduce next-generation Oncodetect MRD test leveraging MAESTRO technology in 2026.

International Expansion Exploration Exploring opportunities to make Cologuard and Cancerguard tests available outside the U.S. market soon.

Peer Comparison

Revenue (TTM)

VTRS

$14.30B

-3.0%

BAX

$11.24B

+5.7%

ICLR

$8.10B

-2.5%

Gross Margin (Latest Quarter)

IONS

96.1%

-0.7pp

BBIO

90.0%

+16.5pp

DOCS

89.9%

+0.2pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
ROIV	$21.13B	-25.4	-18.3%	4.0%
EXAS	$19.80B	-94.6	-8.5%	43.0%
RVMD	$19.78B	-16.8	-63.1%	6.7%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

7.5%

Steady Growth

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

100%

Strong Cash Flow

Deep Research

Next earnings:Apr 29, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data